Key result
Machine learning-guided Lp(a) testing identifies high-risk patients with fewer tests than universal screening.
Why the study?
Elevated Lp(a) is a common CVD risk factor with low testing rates and population-wide screening faces cost and implementation challenges.
Does a machine learning model improve the identification of individuals with elevated Lp(a) compared to universal screening in adults ≥37 years old?
Observational (n=438,579)
Yes
Does a machine learning model improve the identification of individuals with elevated Lp(a) compared to universal screening in adults ≥37 years old?
Answers are grounded in this paper and cite their sources.
A machine learning model using age, height, total cholesterol, and statin use can efficiently prioritize patients for Lp(a) testing, significantly increasing the yield of identifying elevated levels compared to universal screening.
AIMS: Elevated lipoprotein(a) [Lp(a)] is a common risk factor for cardiovascular disease (CVD) affecting ∼1.4 billion people globally, with novel treatments under development. Guidelines recommend one-lifetime measurement, yet <1% are tested. Population-wide screening faces cost and implementation challenges. We developed a machine learning (ML) model to help prioritise patients for Lp(a) testing. METHODS: Ethnicity-calibrated ML models were developed to identify individuals with elevated Lp(a) in UK Biobank. Participants ≥37 years old (N=438,579) were split into feature importance/selection(20%), derivation(60%), and validation(20%) datasets. Performances across risk-enhancing Lp(a) thresholds recommended by clinical guidelines (90, 125, 430 nmol/L) or entry criteria for ongoing Lp(a)-lowering trials (150, 175, 200 nmol/L) were evaluated. External validation was conducted in NHANES III. RESULTS: Screening one million people using a universal approach would identify 222,717 cases above 90 nmol/L and 1950 above 430 nmol/L. In contrast, applying ML-targeted testing using the same number of tests would identify 280,899 (+26%; 95%CI:20-28%) and 6881 (+253%; 95%CI:192-310%) cases, respectively. At the thresholds of 125, 150, 175, and 200 nmol/L, yield increases were 38% (95%CI:35-40%), 51% (95%CI:47-54%), 59% (95%CI:55-63%), and 66% (95%CI:61-71%). Across thresholds 90-430 nmol/L, ML-targeted testing (Number Needed to Screen [NNS] 3.6-145, AUC 0.61-0.84) required 21%-72% fewer tests to identify one million cases. NHANES III validation demonstrated similar performance. Top 4 predictors included age, height (proxy for sex), total cholesterol and statin use. CONCLUSION: A ML-guided approach to prioritise testing for elevated Lp(a) would require fewer tests to identify those above risk-enhancing thresholds or potentially eligible for emerging therapies, offering a scalable interim compromise between the low current testing rates and universal screening aspirations.
No takes yet. Share an insight, caveat, or question.
Stevens et al. (2026) conducted an observational in Elevated lipoprotein(a) (n=438,579). Machine learning-targeted testing vs. Universal screening was evaluated on Identification of cases with Lp(a) >90 nmol/L per one million tests (Yield increase 26%, 95% CI 20-28). Machine learning-targeted testing increased the yield of identifying individuals with Lp(a) >90 nmol/L by 26% compared to a universal screening approach.
Synapse has enriched 10 related papers. Consider them for comparative context: